Source: Virtual Congress 2021 – COVID - 19 biomarkers



Rating:

Share or cite this content

Citations should be made in the following way:
K. Bielosludtseva (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine), T. Kirieieva (Dnipro, Ukraine), B. Basina (Dnipro, Ukraine), N. Krabchenko (Dnipro, Ukraine), M. Krykhtina (Dnipro, Ukraine). What is the best biomarker of COVID-19 pneumonia progression?. 652

Member's Comments

No comment yet.

Related content which might interest you: The best coagulation marker for prediction of COVID-19 pneumonia progression. Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021 Determining the best diagnostic biomarker for sepsis and prognosis assessment Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 What new biomarkers are on the horizon for severe exacerbations? Source: Research Seminar 2021 – Unravelling severe exacerbations of COPD – CICERO an ERS CRC Year: 2021 Low-t3 state a crucial biomarker in determining NIV failure and outcome in pulmonary patient? Source: Annual Congress 2011 - Mechanical ventilation and weaning Year: 2011 How exactly can we predict the prognosis of COPD? Source: Eur Respir J 2006; 28: Suppl. 50, 807s Year: 2006 How to better assess and predict disease progression and treatment response: home-based spirometry, biomarkers or …? Source: International Congress 2019 – High-tech in interstitial lung diseases: just hype and gadgets? Year: 2019 Which is the most effective inflammatory marker in the diagnosis, severity and treatment follow-up of patients with pneumonia? Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting Source: International Congress 2016 – Airway biomarkers Year: 2016 Biomarkers and VAP: results and perspectives Source: Eur Respir Mon 2011; 53: 24-35 Year: 2011 Procalcitonin and C reactive protein as markers of treatment failure in community-acquired pneumonia Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis? Source: Eur Respir J 2016; 48: 279-281 Year: 2016 Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis? Source: Eur Respir J 2016; 48: 281-282 Year: 2016 Treatment of early lung disease – is it possible? Does it work? Source: Annual Congress 2004 - PG19 - Screening for cystic fibrosis: diagnose early - treat early Year: 2004 Monitoring of early lung disease: Is it clinically important to do routine infant lung function test? Source: Annual Congress 2004 - PG19 - Screening for cystic fibrosis: diagnose early - treat early Year: 2004 Biomarkers for fibrotic lung disease - new clinical benchmarks from the lab? Source: Annual Congress 2013 –ME3 Biomarkers for fibrotic lung disease – new clinical benchmarks from the lab? Year: 2013 Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019 How to manage a patient with COPD - early identification and how to prevent progression Source: ERS Satellites 2021 Year: 2021 Are T2 biomarkers of any help in diagnosing asthma? Source: Virtual Congress 2020 – New tools for diagnosis of obstructive diseases Year: 2020